Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc. has demonstrated a robust financial performance, with a trailing twelve-month average selling price (ASP) of $441 per test, reflecting a 9% year-over-year increase, contributing to a significant 19% year-over-year revenue growth for the first nine months of the year. The company has shown efficiency in its operations, evidenced by a rise in average revenue per sales territory from approximately $285,000 two years ago to around $430,000 in Q3, while plans to expand its territories to 45 by the end of 2025 position it for sustained growth. Additionally, Exagen's strategic enhancements to its commercial team leadership and ongoing efforts to improve reimbursement processes are likely to further support its revenue growth trajectory, as indicated by a 38% year-over-year increase in Q3.

Exagen Inc. is experiencing a significant downward adjustment to its future financial outlook, prompted by factors such as a reduced growth projection for 2026, delayed timelines for achieving positive free cash flow, and a decline in peer valuation multiples. The company's anticipated average selling price (ASP) and gross margin expansion are expected to be muted in the near term, leading to downward revisions of revenue estimates in the long term. Furthermore, a notable drop of over 60% in Exagen's stock price following the 3Q25 results suggests investor concerns regarding the loss of key accounts, which has raised questions about growth potential and the timeline for achieving profitability.